Trastuzumab and Combination Chemotherapy in Treating Patients With Locally Recurrent or Metastatic Urinary Tract Cancer

NCT00005831 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

40

Enrollment

NIH

Sponsor class

Conditions

Metastatic Transitional Cell Cancer of the Renal Pelvis and Ureter
Recurrent Bladder Cancer
Recurrent Transitional Cell Cancer of the Renal Pelvis and Ureter
Squamous Cell Carcinoma of the Bladder
Stage IV Bladder Cancer
Transitional Cell Carcinoma of the Bladder

Interventions

BIOLOGICAL: trastuzumab
DRUG: paclitaxel
DRUG: carboplatin
DRUG: gemcitabine hydrochloride
OTHER: laboratory biomarker analysis

Sponsor

National Cancer Institute (NCI)